Skip to main content
padlock icon - secure page this page is secure

Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease

Buy Article:

$68.00 + tax (Refund Policy)

Alzheimer’s disease (AD) is the most prevalent among the aging diseases known as neurodegenerative disorders. Drug design programs over the last two decades were mainly based on the cholinergic, the amyloid or the tau hypothesis. However, none of the new drugs have a real impact on the outcome of the disease. The complex nature of AD has led to new approaches for drug development programs, the multitarget drug design hypothesis. Based on this hypothesis, the generation of multitarget hybrid compounds from previously known active molecules has been one of the most widely used to obtain new candidates for the future treatment of AD. Here, we summarize recent developments based on the hybridization hypothesis to obtain a potential clinical candidate for AD.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Alzheimer's disease; Antioxidants; Drug design; Dual AChE Inhibitors; Emerging targets for AD; Hybrid compounds; Multitarget drugs; Nrf2-EpRE inducers

Document Type: Research Article

Publication date: April 1, 2017

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more